Excellent Phase III results from Zogenix (epilepsy), shares rise 30% in 2 days

California-based Zogenix has announced results from its Phase III Study 1504 clinical trial, designed to assess its investigational therapy ZX008 (fenfluramine hydrochloride), for the treatment of patients with Dravet syndrome, a rare form of epilepsy characterized by severe convulsive seizures. The results showed a 54.7% decrease in convulsive seizures frequency as compared to placebo. Zogenix  has informed it plans to submit an application to EMA and FDA before the end of the year. Zogenix’s share (Nasdaq) have positively reacted, with an approximately 30% increase in two days.

(Source: Zogenix)